Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder

Exclusion Criteria

• •1. Patients who, during the core study, developed any psychiatric condition that requires treatment with medication or that may interfere with study participation and /or study assessments.
• •2. Patients who during the core study developed cardiovascular disorders.
• •3. Pregnant women.
• •4. Patients who developed seizures during the core study.
• •5. Diagnosis of glaucoma, hyperthyroidism, pheochromocytoma.
• •6. Diagnosis or family history of Tourette's syndrome.
• •7. Patients who during the core study developed cerebrovascular disorders such as cerebral aneurysm, vascular abnormalities including vasculitis and stroke